Single infections, Mixed infections, Severe infections in general, Respiratory tract infections, Ear, nose & throat infections, Skin & soft tissue infections, Gastrointestinal, biliary & abdominal infections, Bone & joint infections, Infections associated with hemo & peritoneal dialysis & with continuous ambulatory peritoneal dialysis (CAPD).
3rd Generation Cephalosporin; Antibacterial
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis. A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins.
1 to 6 gram per day 8 or 12 hourly (IM/IV) in the majority of infections, Infants & Children: The usual dosage range for children aged over two months is 30 to 100 mg/kg/day, given as two or three divided doses. Neonates & children up to 2 months: The usual dosage range is 25 to 60 mg/kg/ day as two divided doses.
Known hypersensitivity to Cephalosporin antibiotics.
Local: phlebitis or thrombophlebitis with IV administration; pain and/or inflammation after IM injection. Hypersensitivity: Urticarial rash, fever, pruritus, & very rarely angioedema & anaphylaxis (bronchospasm and/or hypotension), diarrhea, nausea, vomiting, abdominal pain, & very rarely oral thrush or colitis, candidiasis, vaginitis, headache, dizziness, paraesthesia & bad taste.
Pregnancy Category B. Ceftazidime is excreted in human breast milk & caution should be exercised when administered to a nursing woman.
Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma. Patients who receive an acute overdosage should be carefully observed and given supportive treatment.
Store below 25°C, protected from light and moisture. Reconstituted solutions are stable for up to 24 h if stored between 2°-8°C.
.png&w=384&q=75)